A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

NCT06697197 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

413

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: BMS-986482
DRUG: Nivolumab and rHuPH20
DRUG: Nivolumab/relatlimab/rHuPH20
DRUG: Bevacizumab

Sponsor

Bristol-Myers Squibb